362 related articles for article (PubMed ID: 12620735)
1. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk.
Murray CJ; Lauer JA; Hutubessy RC; Niessen L; Tomijima N; Rodgers A; Lawes CM; Evans DB
Lancet; 2003 Mar; 361(9359):717-25. PubMed ID: 12620735
[TBL] [Abstract][Full Text] [Related]
2. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
3. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions.
Soerjomataram I; Lortet-Tieulent J; Parkin DM; Ferlay J; Mathers C; Forman D; Bray F
Lancet; 2012 Nov; 380(9856):1840-50. PubMed ID: 23079588
[TBL] [Abstract][Full Text] [Related]
4. Global burden of disease in young people aged 10-24 years: a systematic analysis.
Gore FM; Bloem PJ; Patton GC; Ferguson J; Joseph V; Coffey C; Sawyer SM; Mathers CD
Lancet; 2011 Jun; 377(9783):2093-102. PubMed ID: 21652063
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population.
Dodhia H; Phillips K; Zannou MI; Airoldi M; Bevan G
J Hypertens; 2012 Jan; 30(1):217-26. PubMed ID: 22080224
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.
Barton P; Andronis L; Briggs A; McPherson K; Capewell S
BMJ; 2011 Jul; 343():d4044. PubMed ID: 21798967
[TBL] [Abstract][Full Text] [Related]
8. The impact of prevention on reducing the burden of cardiovascular disease.
Kahn R; Robertson RM; Smith R; Eddy D
Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
[TBL] [Abstract][Full Text] [Related]
9. The global impact of noncommunicable diseases: estimates and projections.
Manton KG
World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
[TBL] [Abstract][Full Text] [Related]
10. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
11. Estimated effect of increased diagnosis, treatment, and control of diabetes and its associated cardiovascular risk factors among low-income and middle-income countries: a microsimulation model.
Basu S; Flood D; Geldsetzer P; Theilmann M; Marcus ME; Ebert C; Mayige M; Wong-McClure R; Farzadfar F; Saeedi Moghaddam S; Agoudavi K; Norov B; Houehanou C; Andall-Brereton G; Gurung M; Brian G; Bovet P; Martins J; Atun R; Bärnighausen T; Vollmer S; Manne-Goehler J; Davies J
Lancet Glob Health; 2021 Nov; 9(11):e1539-e1552. PubMed ID: 34562369
[TBL] [Abstract][Full Text] [Related]
12. Risk for cardiovascular disease in the elderly and associated Medicare costs: the Framingham Study.
Schauffler HH; D'Agostino RB; Kannel WB
Am J Prev Med; 1993; 9(3):146-54. PubMed ID: 8347365
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.
Bovet P; Shamlaye C; Gabriel A; Riesen W; Paccaud F
BMC Public Health; 2006 Jan; 6():9. PubMed ID: 16423280
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
Rubió PP
Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.
Lim SS; Gaziano TA; Gakidou E; Reddy KS; Farzadfar F; Lozano R; Rodgers A
Lancet; 2007 Dec; 370(9604):2054-62. PubMed ID: 18063025
[TBL] [Abstract][Full Text] [Related]
17. [Meta-analysis of the Italian studies on short-term effects of air pollution].
Biggeri A; Bellini P; Terracini B;
Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
[TBL] [Abstract][Full Text] [Related]
18. Integrated screening and treatment services for HIV, hypertension and diabetes in Kenya: assessing the epidemiological impact and cost-effectiveness from a national and regional perspective.
Kasaie P; Weir B; Schnure M; Dun C; Pennington J; Teng Y; Wamai R; Mutai K; Dowdy D; Beyrer C
J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25499. PubMed ID: 32562353
[TBL] [Abstract][Full Text] [Related]
19. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study.
Murray CJ; Lopez AD
Lancet; 1997 May; 349(9062):1347-52. PubMed ID: 9149696
[TBL] [Abstract][Full Text] [Related]
20. Selected major risk factors and global and regional burden of disease.
Ezzati M; Lopez AD; Rodgers A; Vander Hoorn S; Murray CJ;
Lancet; 2002 Nov; 360(9343):1347-60. PubMed ID: 12423980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
